Akela and Nventa announce merger

31-Mar-2009 - Akela Pharma Inc. and Nventa Biopharmaceuticals announced the execution of an arrangement agreement to combine the two companies by way of a plan of arrangement under the Business Corporations Act (British Columbia). The board of directors of both companies unanimously approved the agreement. ...

Nventa Wins European Patent Challenge Covering Lead Product Candidate HspE7 and Other HPV Therapeutics

31-Jul-2008 - Nventa Biopharmaceuticals Corporation announced that it has received a favorable decision from the Technical Board of Appeal of the European Patent Office (EPO) for the company's European Patent Number 1,002,110. This patent, which allows exclusively through 2018, covers compositions of fusion ...

Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial

30-Jul-2008 - Nventa Biopharmaceuticals Corporation announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate. HspE7 is a therapeutic treatment for patients with cervical intraepithelial neoplasia, or CIN, a ...

Nventa assembles group of international experts for its Clinical and Scientific Advisory Board

01-Aug-2007 - Nventa Biopharmaceuticals Corporation announced that it has assembled a Clinical and Scientific Advisory Board. The Board will be instrumental in providing strategic and scientific guidance on the Company's development programs, including its lead HspE7 clinical program for human papillomavirus ...

Nventa granted U.S. patent covering heat shock protein fusion to treat anogenital warts

07-May-2007 - Nventa Biopharmaceuticals Corporation announced that the U.S. Patent and Trademark Office has issued Patent Number 7,211,411 B2 to Nventa covering the use of HspE7, the Company's investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, to treat patients with anogenital ...

Nventa granted U.S. patent covering heat shock protein fusion to treat influenza

01-Feb-2007 - Nventa Biopharmaceuticals Corporation announced that the U.S. Patent and Trademark Office has issued Patent Number 7,157,089 to Nventa. The patent provides coverage for compositions of fusion proteins comprised of an influenza antigen fused to a heat shock protein (Hsp), as well as DNA encoding ...

Nventa strengthens patent portfolio with two new European Patents for HPV-related diseases

22-Jun-2006 - Nventa Biopharmaceuticals Corporation announced that the European Patent Office has granted two patents to Nventa related to HspE7, its investigational therapeutic vaccine for the treatment of human papillomavirus (HPV)-related diseases. HspE7 consists of a heat shock protein (Hsp) covalently ...

Nventa announces positive HspE7 data from NCI-sponsored clinical trial in HIV-positive patients

First Clinical Evidence that HspE7 May Have Activity in Immunocompromised Patients

19-Jun-2006 - Nventa Biopharmaceuticals Corporation announced results, recently published in the journal AIDS, from a clinical trial to test HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, on patients with high-grade anal intraepithelial neoplasia (AIN), or ...

Nventa granted European patent covering heat shock protein fusion to treat influenza

09-Jun-2006 - Nventa Biopharmaceuticals Corporation announced that the European Patent Office has granted Patent Number EP 941,315 to Nventa, covering compositions of fusion proteins comprised of an influenza antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins. "Our ...